Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 15/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091179 | 0.90 | LTB4R2 (0.52) | LTB4R2AGTR1 | |
| SCHEMBL5099501 | 0.84 | LTB4R2 (0.57) | LTB4R2AGTR1 | |
| SCHEMBL5091114 | 0.82 | LTB4R2 (0.43) | LTB4R2AGTR1 | |
| SCHEMBL5089013 | 0.82 | LTB4R2 (0.48) | LTB4R2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL94332 | 0.73 | AGTR1 (0.74) | AGTR1ABCC3ABCC4ABCB11CYP3A4 | |
| SCHEMBL16239690 | 0.73 | AGTR1 (0.59) | AGTR1ABCC3ABCC4ABCB11CYP3A4 | |
| SCHEMBL28459370 | 0.71 | AGTR1 (0.56) | LTB4R2AGTR1ABCB11AGTR2 | |
| SCHEMBL2930431 | 0.70 | AGTR1 (0.66) | LTB4R2AGTR1ABCB11AGTR2 | |
| SCHEMBL28456708 | 0.70 | AGTR1 (0.66) | LTB4R2AGTR1ABCB11AGTR2 | |
| SCHEMBL12787574 | 0.70 | AGTR1 (0.53) | LTB4R2AGTR1ABCB11AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | LTB4R2 1259/4885AGTR1 41/4885ABCC3 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.